View Larger Image
This third of a four-part series describes a powerful, simple tool that can provide a strong first step for improving project team decision-making.
Late last year the European Medicines Agency granted marketing approval for the Western world's first gene therapy product, Glybera. During this SKYPE interview, James M. Wilson, M.D., Ph.D., one of the researchers who led the Glybera team, discusses the ups and downs and ins and outs of not only developing the new therapeutic but also gaining regulatory approval for the novel product. JMW is an inventor on the AAV1 patent and will receive royalties from the sales of Glybera.
Leverage our free Application Note Library to make smarter technology and service purchasing decisions. We will post technical white papers and application notes from leading tool and service providers to keep you up-to-date.
Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?
Be sure to add email@example.com
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2013 Genetic Engineering & Biotechnology News All Rights Reserved